Welcome to our dedicated page for Bio-Key Intl SEC filings (Ticker: BKYI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to connect BIO-key’s fingerprint technology buzz with concrete numbers? Each BIO-key International SEC filing hides vital clues—from government contract wins to PortalGuard license renewals—but the language can be as technical as the biometrics it describes.
Stock Titan solves that problem in seconds. Our AI-powered summaries pull plain-English insights from every 10-K and 10-Q, so the next time you search for “BIO-key quarterly earnings report 10-Q filing” or wonder how R&D spending impacts margins, the answers appear before you even open the PDF. Need real-time alerts on “BIO-key insider trading Form 4 transactions” or “BIO-key executive stock transactions Form 4”? We stream them the moment they hit EDGAR, complete with context on historical buying patterns.
All major forms are covered:
- 10-K annual report—our AI spots biometric revenue trends, making “BIO-key annual report 10-K simplified” more than a promise.
- 10-Q quarterly updates—track segment growth without wading through accounting jargon.
- 8-K current reports—get “BIO-key 8-K material events explained” when new cybersecurity contracts close.
- DEF 14A proxy—quickly see “BIO-key proxy statement executive compensation” details.
Investors use these insights to compare license versus hardware sales, monitor insider confidence, and gauge cash needs for future biometric R&D. Whether you type “understanding BIO-key SEC documents with AI” or ask, “where do I find BIO-key earnings report filing analysis,” this page answers instantly—no scrolling, no spreadsheets, just clarity.
BIO-key International, Inc. (BKYI) filed its Definitive Proxy Statement (DEF 14A) for the 2025 Annual Meeting of Stockholders, scheduled for August 8 2025 at 10:00 a.m. (ET) at the company’s Holmdel, NJ headquarters. The record date is June 20 2025, when 6,848,775 common shares were outstanding, with each share entitled to one vote and no cumulative voting rights.
Shareholders will vote on six proposals: (1) election of five directors to serve until the 2026 meeting; (2) ratification of Bush & Associates CPA LLC as independent registered public accounting firm for FY 2025; (3) an advisory “say-on-pay” vote on executive compensation; (4) an amendment to the 2023 Stock Incentive Plan; (5) an amendment to the 2021 Employee Stock Purchase Plan; and (6) other routine business. Boxes for a preliminary proxy, confidential treatment, additional materials, and soliciting material are all unchecked, confirming that this filing is the definitive statement.
The proxy materials, together with the company’s Form 10-K for the year ended December 31 2024, were first mailed on or about June 27 2025. Registered shareholders may vote in person, by mail, telephone, or internet; beneficial owners must follow their broker’s instructions. Brokers lack discretionary authority to vote uninstructed shares on Proposals 1, 3, 4, or 5, potentially resulting in broker non-votes for those items.
The filing includes a detailed table of contents covering governance, principal stockholders, executive and director compensation, and full text of the amended stock plans (Appendices A & B). No filing fee was required. Aside from the requested plan amendments, the proxy does not disclose new financial metrics, acquisitions, or other extraordinary actions.
FAQ
What is the current stock price of Bio-Key Intl (BKYI)?
What is the market cap of Bio-Key Intl (BKYI)?
What is the core business of BIO-key International Inc?
How does BIO-key generate revenue?
What industries does BIO-key serve?
What differentiates BIO-key from other biometric technology providers?
How are BIO-key’s solutions integrated into existing IT infrastructures?
What are the primary benefits of BIO-key's biometric authentication technology?
How does BIO-key support enterprise-level security requirements?
Can BIO-key’s solutions be deployed in consumer applications as well?
